2. Search Result
Search Result
Pathways Recommended: Antibody-drug Conjugate/ADC Related
Results for "

deliver drugs

" in MedChemExpress (MCE) Product Catalog:

44

Inhibitors & Agonists

2

Screening Libraries

2

Fluorescent Dyes

10

Biochemical Assay Reagents

4

Peptides

4

Inhibitory Antibodies

1

Natural
Products

1

Click Chemistry

8

Oligonucleotides

Cat. No. 상품명 Target 연구분야 Chemical Structure
  • HY-164789
    Sacituzumab tirumotecan

    SKB264; MK-2870

    		 Antibody-Drug Conjugates (ADCs) TROP2 Cancer
    Sacituzumab tirumotecan is an antibody-drug conjugate and TROP2-directed, topoisomerase I inhibitor payload-delivering agent, with a TROP2 EC50 of 2.787 ng/ml, TROP2 Ka of 0.3083 nM, and topoisomerase I IC50 of 0.7 μmol/L. Sacituzumab tirumotecan can be used for the research of metastatic triple-negative breast cancer, and metastatic non-small cell lung cancer .
    Sacituzumab tirumotecan
  • HY-164992
    Trastuzumab vedotin
    2 Publications Verification

    MRG002; Trastuzumab MMAE

    		 Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
    Trastuzumab vedotin
  • HY-W127512
    5β-Cholanic acid
    1 Publications Verification

    		 Drug Intermediate Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid
  • HY-171124
    Tilatamig samrotecan

    AZD9592

    		 Antibody-Drug Conjugates (ADCs) EGFR c-Met/HGFR Topoisomerase DNA/RNA Synthesis Cancer
    Tilatamig samrotecan (AZD9592) is an anti-EGFR/c-MET antibody-drug conjugate (ADC). Tilatamig samrotecan consists of an anti-EGFR/c-MET antibody with the drug-linker conjugate being AZ14170133 (HY-145399) (a topoisomerase I (TOP1i) inhibitor payload). Tilatamig samrotecan induces multiple DNA damage response pathway markers (like ATM, ATR, γH2AX). Tilatamig samrotecan selectively binds to EGFR and c-MET, delivering the cytotoxic payload. Tilatamig samrotecan exerts anti-tumor activity in vivo. Tilatamig samrotecan can be used for non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) research .
    Tilatamig samrotecan
  • HY-141126
    Azido-PEG4-alpha-D-mannose

    		Biochemical Assay Reagents Cancer
    Azido-PEG4-alpha-D-mannose is a PEG linker that combines an azide group with an alpha-D-mannose moiety. Azido-PEG4-alpha-D-mannose is a click chemistry reagent, it contains an Azide group and can undergo copper-catalyzed azide-alkyne cycloaddition reaction (CuAAc) with molecules containing Alkyne groups. It can also undergo strain-promoted alkyne-azide cycloaddition (SPAAC) reactions with molecules containing DBCO or BCN groups. Azido-PEG4-alpha-D-mannose has the targeting property of mannose, which can accurately deliver drugs to specific cells or tissues to improve the therapeutic effect of drugs .
    Azido-PEG4-alpha-D-mannose
  • HY-N9459
    2-Amino-2-deoxyglucose hydrochloride

    D-Glucosamine Hydrochloride

    		 GLUT Infection Neurological Disease Cancer
    2-Amino-2-deoxyglucose hydrochloride (D-Glucosamine Hydrochloride) is a glucose analog that is specifically recognized and transported by the cell membrane GLUT1. 2-Amino-2-deoxyglucose hydrochloride acts as a tumor-targeting ligand and a guiding molecule for the synthesis of prodrug conjugates, thus delivering drugs precisely to tumor cells. 2-Amino-2-deoxyglucose hydrochloride is applicable to diagnostic imaging and therapeutic efficacy monitoring of solid tumors and various cancers (e.g., breast cancer, glioblastoma). 2-Amino-2-deoxyglucose hydrochloride also helps bacteria resist lysozyme digestion by integrating into the non-N-acetylated residues of Streptococcus pneumoniae peptidoglycan. 2-Amino-2-deoxyglucose hydrochloride is used in studies on tumor metabolism and the exploration of bacterial drug resistance mechanisms .
    2-Amino-2-deoxyglucose hydrochloride
  • HY-P5623
    RVG
    1 Publications Verification

    RVG29; RDP; Rabies Virus Glycoprotein-29

    		 nAChR Interleukin Related Neurological Disease Inflammation/Immunology
    RVG (RVG29) is a blood-brain barrier-permeable peptide derived from rabies virus glycoprotein, which binds to the α-7 subunit of neuronal nicotinic acetylcholine receptor (AchR). RVG efficiently delivers drugs to nerve cells and antigen-presenting cells in a targeted manner, and enhances the efficiency of antigen presentation and drug delivery .
    RVG
  • HY-157763
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1

    		PROTAC-Linker Conjugates for PAC Btk Cancer
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 is a cleavable linker-payload conjugate and cereblon-binding BTK bifunctional degrader. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 induces BTK degradation and exerts cytotoxic effects when delivered via CD79b monoclonal antibody. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1, when formulated as a CD79b antibody-drug conjugate, achieves sustained in vivo BTK degradation in tumor-bearing mice with reduced systemic payload exposure. Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1 can be used for the research of activated b-cell-like diffuse large b-cell lymphoma (ADC linker: (HY-130944); PROTAC: (HY-163295)) .
    Mal-PEG1-Val-Cit-PABC-diphosphate-BTK degrader-1
  • HY-156174
    E104

    		Toll-like Receptor (TLR) ADC Payload Cancer
    E104 (compound 1) is a potent and selective TLR7 agonist. E104 can be delivered by antibody-drug conjugate (ADC) technology to elicit potent anticancer activity. E104 induces the activation of mouse macrophages and hPBMCs .
    E104
  • HY-115415
    1,2-Distearoyl-sn-glycero-3-phosphate sodium

    		Liposome Others
    1,2-Distearoyl-sn-glycero-3-phosphate, sodium salt is a phospholipid commonly used as a component of liposome formulations and drug delivery systems. 1,2-Distearoyl-sn-glycero-3-phosphate, sodium salt has unique chemical properties that make it an effective tool for encapsulating drugs and delivering them to specific targets in the body. It acts as a stabilizer and emulsifier, which can improve the solubility and bioavailability of drugs.
    1,2-Distearoyl-sn-glycero-3-phosphate sodium
  • HY-106031
    F-14512

    		Topoisomerase DNA/RNA Synthesis Cancer
    F-14512 is an anticancer agent that utilizes the polyamine transport system (PTS) to selectively deliver polyamine-containing drugs to cancer cells. F-14512 enhances the affinity of polyamines for DNA, thereby inhibiting topoisomerase II and achieving selective cellular uptake. F-14512 exhibits significant cytotoxicity against cells with high PTS activity and induces DNA damage. F-14512 demonstrates potent antitumor activity in the MX1 breast tumor xenograft model. F-14512 can be used to study breast cancer .
    F-14512
  • HY-177578
    NN3201

    		Antibody-Drug Conjugates (ADCs) c-Kit Apoptosis Microtubule/Tubulin ERK Akt Caspase Cancer
    NN3201 is a c-Kit-targeting antibody-drug conjugate (ADC) with high affinity (KD = 0.19 pM). NN3201 is composed of 4-(3-Tosyl-2-(tosylmethyl)propanoyl)benzoic acid-glu(PEG24-Me)-val-cit-NH-benzyloxyformic acid-MMAE (HY-178219) and an anti-c-Kit human monoclonal antibody NN2101 (HY-P991293). NN3201 rapidly internalizes and inhibits stem cell factor (SCF)-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits no Fc-mediated effector functions antibody-dependent cell-mediated cytotoxicity (ADCC)/complement-dependent cytotoxicity (CDC) due to reduced FcγR binding. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models. NN3201 can be used in small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) and acute myeloid leukemia (AML) research [1][2].
    NN3201
  • HY-156829A
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1)

    		Biochemical Assay Reagents Cancer
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) is a matrix materia, with lactic acid (LA):glycolic acid (GA) = 15:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1)
  • HY-137501
    306-O12B-3

    		Liposome Others
    306-O12B-3 is a lipidoid that can efficiently deliver ASO both in vitro and in vivo. 306-O12B-3 is used to transport small molecule drugs across the blood-brain barrier (BBB) .
    306-O12B-3
  • HY-P991742
    LY4101174 Antibody

    15A7.5; ETx-22 Antibody

    		 ADC Antibody Cancer
    LY4101174 Antibody is an ADC antibody. LY4101174 is an antibody-drug conjugate (ADC) that targets the nectin-4 protein present on the surface of certain cancer cells. It can directly deliver a potent chemotherapy agent (Exatecan (HY-13631)) to the tumor site and is used for the study of advanced cancers, such as urothelial carcinoma, triple-negative breast cancer, and non-small cell lung cancer .
    LY4101174 Antibody
  • HY-140696C
    m-PEG20000-OH

    mPEG20000-Hydroxy; Polyethylene glycol monomethyl ether 20000

    		 PROTAC Linkers Cancer
    m-PEG20000-OH can be used as a macroinitiator to participate in the synthesis of amphiphilic block copolymers. Nanoscale micelles can be prepared by using amphiphilic block copolymers to deliver active drugs. Paclitaxel (HY-B0015), a hydrophobic anticancer agent encapsulated in micelles, has stronger activity in killing cancer cells than free Paclitaxel. And it preferentially accumulates in tumor tissue with only limited distribution in healthy organs.
    m-PEG20000-OH
  • HY-156829
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1)

    		Biochemical Assay Reagents Cancer
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) is a matrix materia, with lactic acid (LA)：glycolic acid (GA) = 1:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .
    PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1)
  • HY-153137
    Tri-N-tridecyl 3-(ethyl(methyl)amino)propanoate

    304O13

    		 Liposome Cancer
    Tri-N-tridecyl 3-(ethyl(methyl)amino)propanoate is a biodegradable lipid prepared by the conjugate addition of alkylamines to acrylates. Tri-N-tridecyl 3-(ethyl(methyl)amino)propanoate can be used in various drug delivery systems to deliver polynucleotides, siRNA for example .
    Tri-N-tridecyl 3-(ethyl(methyl)amino)propanoate
  • HY-178219
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE

    		Drug-Linker Conjugates for ADC Microtubule/Tubulin Apoptosis Cancer
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE is a drug-linker conjugate for ADC. Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE contains a linker and bioactive small molecule toxins MMAE (HY-15162). Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE can conjugate with NN2101 (HY-P991293) (anti c-Kit) for synthesizing NN3201. NN3201 rapidly internalizes and inhibits SCF-driven signaling, thereby delivering its payload to induce cell cycle arrest and apoptosis. NN3201 exhibits significant c-Kit-dependent anti-tumor efficacies in various tumor models, such as small cell lung cancer (SCLC) and gastrointestinal stromal tumor (GIST) .
    Bis-sulfone-(PEG24)-Glu-Val-Cit-PAB-MMAE
  • HY-164429
    VIP236

    		Integrin Elastase Cancer
    VIP236 is a small-molecule drug conjugate targeting αvβ3 integrin. VIP236 achieves tumor homing via specific binding to αvβ3 integrin and delivers its payload to the tumor microenvironment. The linker of VIP236 is cleavable by neutrophil elastase, which is highly expressed in the tumor microenvironment, to release the payload 7-ethylcamptothecin. This payload induces DNA damage by inhibiting topoisomerase 1, thereby exerting anti-tumor effects. VIP236 exhibits excellent plasma stability and tumor targeting property, with a tumor/plasma payload ratio 10-fold higher than that of the single administration. It effectively induces tumor regression, reduces metastasis formation, and shows good tolerance in mouse models. VIP236 has been used in studies related to non-small cell lung cancer, clear cell renal cell carcinoma, colon cancer, triple-negative breast cancer, small cell lung cancer, and metastatic solid tumors .
    VIP236
  • HY-P3402
    HBpep-K

    		Amino Acid Derivatives Others
    HBpep-K is a peptide that can form co aggregated droplets. HBpep-K can efficiently load and deliver small peptides, proteins, and mRNA. HBpep-K can protect mRNA from RNase degradation. HBpep-K is commonly used for drug delivery .
    HBpep-K
  • HY-P3402A
    HBpep-K acetate

    		Amino Acid Derivatives Others
    HBpep-K acetate is a peptide that can form co aggregated droplets. HBpep-K acetate can efficiently load and deliver small peptides, proteins, and mRNA. HBpep-K acetate can protect mRNA from RNase degradation. HBpep-K acetate is commonly used for drug delivery .
    HBpep-K acetate
  • HY-158459
    A2G2F2 glycan

    A2G2F2(a1-3) glycan

    		 E-Selectin Biochemical Assay Reagents Others
    A2G2F2 glycan (A2G2F2(a1-3) glycan) is a Lewis X polysaccharide containing two Lewis X epitopes and is a symmetric N-glycan. SLeX is a ligand for the cell adhesion molecule E-selectin, which is specifically expressed at sites of inflammatory lesions. Designing SLeX-polysaccharide conjugates to deliver drugs to inflammatory lesions .
    A2G2F2 glycan
  • HY-W591449
    DOPE-PEG2000-Azide

    		Liposome Cancer
    DOPE-PEG2000-Azide is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .
    DOPE-PEG2000-Azide
  • HY-P10947
    MACTIDE-V

    		Epigenetic Reader Domain YAP Cancer
    MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 + tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .
    MACTIDE-V
  • HY-P99881
    Rolinsatamab talirine

    ABBV 176

    		 Antibody-Drug Conjugates (ADCs) Cancer
    Rolinsatamab talirine (ABBV 176) is a prolactin receptor (PRLR)-targeting antibody-drug conjugate (ADC), compoused of Rolinsatamab (HY-P99238) and SGD-1882 (HY-101127). Rolinsatamab talirine binds to PRLR to deliver a cytotoxin to tumor cells. Rolinsatamab talirine induces DNA damage, and exhibits cytotoxicity against multiple breast tumor models, including triple negative and low PRLR-expressing models. Rolinsatamab talirine demonstrates enhanced anti-tumor activity in several breast cancer models. Rolinsatamab talirine can be used for the research of breast cancer, hepatocellular carcinoma, ovarian cancer, endometrial cancer, prostate cancer, colorectal cancer, adrenocortical carcinoma, and solid tumors .
    Rolinsatamab talirine
  • HY-176512
    FO-32

    		Liposome Cancer
    FO-32 is an ionizable cationic lipid with a pKa of 6.46 and can be used to generate lipid nanoparticles (LNPs) to deliver mRNA in vivo. FO-32 can efficiently deliver mRNA to ferret lungs. FO-32 can be studied in research on optimizing drug delivery .
    FO-32
  • HY-W440698
    Cholesterol-PEG2000-Acid

    		Liposome Cancer
    Cholesterol-PEG2000-Acid is a polydisperse PEG derivative which can be used to create liposome as drug carrier for delivering therapeutic agents into tissues.
    Cholesterol-PEG2000-Acid
  • HY-W440897
    DSPE-PEG3400-SH

    		Biochemical Assay Reagents Others
    DSPE-PEG3400-SH is a maleimide reactive PEG lipid. The amphiphilic polymer forms lipid bilayer in water and can be used to prepare liposomes for drug nanocarriers to deliver mRNA, DNA or siRNA.
    DSPE-PEG3400-SH
  • HY-W440928
    Stearic acid-PEG3400-NHS

    		Liposome Others
    Stearic acid-PEG3400-NHS is a phospholipid polyPEG which can self-assemble in water to form lipid bilayer. The polymer can be used to prepare liposomes as drug carrier to deliver nutrients/therpeutic agents, such as mRNA or DNA.
    Stearic acid-PEG3400-NHS
  • HY-158918
    4-CF3-TPP-DC

    4-CF3-Triphenylphosphonium-DC

    		 Biochemical Assay Reagents Others
    4-CF3-TPP-DC (4-CF3-Triphenylphosphonium-DC) is an inert mitochondrial targeting carrier, that delivers target drugs and probes to mitochondria without causing mitochondrial depolarization and cytotoxicity in cell C2C12 .
    4-CF3-TPP-DC
  • HY-174283
    Tri-valent linker-3

    		Biochemical Assay Reagents Others
    Tri-valent linker-3 is a linker targeting Polymyxin B (PMB) and can be used to synthesize PMB-based drug delivery systems. Polymyxin B carries molecular payloads (e.g., nucleic acid agents) through the linker and binds megalin (a cell surface factor on the surface of target cells) with high affinity, thereby delivering the payload to tissues or cells .
    Tri-valent linker-3
  • HY-158458
    A2[3]G1F1(α-1-3) glycan

    A2[3]G1F1(a1-3) glycan

    		 Biochemical Assay Reagents Others
    A2[3]G1F1(α-1-3) glycan (A2[3]G1F1(a1-3) glycan) is an asymmetric Lewis X polysaccharide and N-glycan. SLeX is a ligand for the cell adhesion molecule E-selectin, which is specifically expressed at sites of inflammatory lesions. Designing SLeX-polysaccharide conjugates to deliver drugs to inflammatory lesions .
    A2[3]G1F1(α-1-3) glycan
  • HY-153725
    17:1 Lyso PC

    		Liposome Cancer
    17:1 Lyso PC is a liposome to simulate biological phospholipid membrane. Liposomes are the main component of vesicles with concentric phospholipid bilayer membranes, which can be used to construct drug delivery systems for anti-cancer and anti-infection fields. Highly polar water-soluble payloads can be trapped in the internal aqueous space of liposomes, while lipophilic payloads can partition into and become part of the lipid bilayer. Especially for delivering antisense oligonucleotides, it can overcome problems such as inefficient cellular uptake and rapid loss in the body .
    17:1 Lyso PC
  • HY-106031A
    F-14512 hydrochloride

    		Topoisomerase DNA/RNA Synthesis Cancer
    F-14512 hydrochloride is an anticancer agent that utilizes the polyamine transport system (PTS) to selectively deliver polyamine-containing drugs to cancer cells. F-14512 hydrochloride enhances the affinity of polyamines for DNA, thereby inhibiting topoisomerase II and achieving selective cellular uptake. F-14512 hydrochloride exhibits significant cytotoxicity against cells with high PTS activity and induces DNA damage. F-14512 hydrochloride demonstrates potent antitumor activity in the MX1 breast tumor xenograft model. F-14512 hydrochloride could be used to study breast cancer .
    F-14512 hydrochloride
  • HY-158457
    A2[3]G1 N-glycan

    N/A

    		 Biochemical Assay Reagents Others
    A2[3]G1 N-glycan (N/A) is a Lewis sugar. SLeX is a ligand for the cell adhesion molecule E-selectin, which is specifically expressed at sites of inflammatory lesions. Designing SLeX-polysaccharide conjugates to deliver drugs to inflammatory lesions .
    A2[3]G1 N-glycan
  • HY-158522
    A2[3]G1 & A2[6]G1 glycan (G1), 2-AB labelled

    A2[3]G1 & A2[6]G1 N-linked oligosaccharide, 2-AB labelled

    		 Biochemical Assay Reagents Others
    A2[3]G1 & A2[6]G1 glycan (G1), 2-AB labeled Lewis sugar. SLeX is a ligand for the cell adhesion molecule E-selectin (E-selectin), which is specifically expressed at sites of inflammatory lesions. Designing SLeX-polysaccharide conjugates to deliver drugs to inflammatory lesions .
    A2[3]G1 & A2[6]G1 glycan (G1), 2-AB labelled
  • HY-158495
    A2 glycan (G0), 2-AA labelled

    A2 N-linked oligosaccharide, 2-AA labelled

    		 Biochemical Assay Reagents Others
    A2[3]G1 & A2[6]G1 glycan (G1), 2-AB labeled Lewis sugar. SLeX is a ligand for the cell adhesion molecule E-selectin (E-selectin), which is specifically expressed at sites of inflammatory lesions. Designing SLeX-polysaccharide conjugates to deliver drugs to inflammatory lesions .
    A2 glycan (G0), 2-AA labelled
  • HY-185279
    Risvutatug rezetecan

    HS-20093; GSK5764227

    		 Antibody-Drug Conjugates (ADCs) CD276/B7-H3 Cancer
    Risvutatug rezetecan (HS-20093; GSK5764227) is a B7-H3-targeting antibody-drug conjugate (ADC). Risvutatug rezetecan binds to B7-H3 on tumor cells and delivers a topoisomerase I inhibitor payload via a tumor microenvironment-responsive cleavable linker. Risvutatug rezetecan is applicable for the research of extensive-stage small cell lung cancer and non-small cell lung cancer .
    Risvutatug rezetecan
  • HY-185484
    MDX-1203

    BMS-936561

    		 Antibody-Drug Conjugates (ADCs) Transmembrane Glycoprotein Cancer
    MDX-1203 (BMS-936561) is an antibody-drug conjugate targeting CD70. MDX-1203 binds to CD70 and mediates the specific delivery of its conjugated cytotoxic payload to tumors. MDX-1203 delivers a DNA alkylating payload into cells. MDX-1203 can be used in research related to advanced clear cell renal cell carcinoma and relapsed/refractory B-cell non-Hodgkin lymphoma .
    MDX-1203
  • HY-W127512R
    5β-Cholanic acid (Standard)

    		Drug Intermediate Reference Standards Others
    5β-Cholanic acid is a hydrophobic modifier used to modify polymer carriers. 5β-Cholanic acid can improve the acid stability, cell penetration efficiency and drug sustained release ability of nanocarriers, and optimize the oral effectiveness of delivered molecules. 5β-Cholanic acid can covalently bind to Glycol chitosan (GC) to form a GC-CA conjugate, which optimizes the hydrophobic anchoring ability of nanoparticles and enables them to be stably adsorbed on the surface of PLGA nanoparticles. Such nanoparticles can resist dissociation in the gastric acid environment and maintain positive charge to enhance endocytic uptake by intestinal epithelial cells (such as Caco-2 cells). 5β-Cholanic acid can be used in the development of drug delivery systems .
    5β-Cholanic acid (Standard)
  • HY-P992340
    CTB006

    		Radionuclide-Drug Conjugates (RDCs) TNF Receptor Cancer
    CTB006 is a monoclonal antibody targeting a humanized chimeric recombinant anti-DR5. CTB006 specifically binds to and activates DR5, thereby inducing tumor cell apoptosis, inhibiting tumor growth and reducing tumor drug resistance. 177Lu-radiolabeled CTB006 can deliver targeted radiotherapy to tumor cells; while 89Zr- or 177Lu-labeled CTB006 can serve as a PET/CT imaging agent for detecting DR5 expression levels in preclinical tumor models and screening cancers with DR5 overexpression. CTB006 can be applied to research related to gastrointestinal cancer, colorectal cancer and other solid tumors .
    CTB006
  • HY-183866
    MPD-1

    Maleimide-KGDEVD-doxorubicin

    		 Peptide-Drug Conjugates (PDCs) HSP IFNAR Cancer
    MPD-1 (Maleimide-KGDEVD-doxorubicin) is a peptide drug conjugate (PDC). MPD-1 releases Doxorubicin (HY-15142) via radiation-activated caspase-3 cleavage, triggering a cytotoxic amplification cascade at the tumor site. MPD-1 enhances CD8 + T cell tumor infiltration, and activates antigen-presenting cells. MPD-1 enables dual-trigger payload release, amplifies cytotoxicity via in situ feedback, and selectively delivers payload to tumor microenvironments via enhanced albumin metabolism and macropinocytosis. MPD-1 exhibits antitumor efficacy in mouse colorectal cancer models. MPD-1 can be used for the research of colorectal cancer .
    MPD-1
  • HY-P992000
    F8-IL-4

    		Interleukin Related Inflammation/Immunology
    F8-IL-4 is an immune cytokine targeting IL-4. F8-IL-4 specifically delivers IL-4 to inflammatory sites via binding to targets expressed on neovascular vessels. F8-IL-4 alleviates collagen-induced arthritis in mice by regulating T cell subsets and macrophage polarization. When combined with Dexamethasone (HY-14648), F8-IL-4 produces a synergistic and long-lasting therapeutic effect, and prevents arthritis recurrence after drug withdrawal by maintaining anti-inflammatory cell phenotypes and cytokine profiles. F8-IL-4 can be used in the research of collagen-induced arthritis .
    F8-IL-4

온라인 문의

Your information is safe with us. * Required Fields.

호칭

  

Country or Region *

고객명 *

 

회사명 *

Department *

     

메일주소 *

 

상품명 *

Cat. No.

  

Requested quantity *

전화번호 *

     

비고

온라인 문의

Inquiry Information

상품명:
Cat. No.:
수량:
MCE Japan Authorized Agent: